TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
BioArctic AB Class B ( ($SE:BIOA.B) ) just unveiled an announcement.
BioArctic AB announced that its partner Eisai will present new data on their Alzheimer’s treatment, lecanemab, at the CTAD conference. The presentations will cover long-term treatment benefits, safety, and real-world clinical practice insights, potentially impacting the company’s market positioning and offering new options for Alzheimer’s treatment.
The most recent analyst rating on ($SE:BIOA.B) stock is a Buy with a SEK328.00 price target. To see the full list of analyst forecasts on BioArctic AB Class B stock, see the SE:BIOA.B Stock Forecast page.
More about BioArctic AB Class B
BioArctic AB is a biopharmaceutical company focused on developing treatments for neurodegenerative diseases, particularly Alzheimer’s disease. Their primary product, Leqembi, is an antibody developed in collaboration with Eisai, targeting amyloid-beta protofibrils, which are believed to contribute to Alzheimer’s progression.
Average Trading Volume: 308,954
Technical Sentiment Signal: Buy
Current Market Cap: SEK26.13B
See more data about BIOA.B stock on TipRanks’ Stock Analysis page.